InMed Pharmaceuticals Inc (INM) — Titan Protect Analysis

INM

InMed Pharmaceuticals Inc

Healthcare · ·

$1.58

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$5M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-0.25

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

-172.2%

How much profit the company keeps from each dollar of revenue

ROE

-112.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

NONE

Consensus view from ? analysts covering this stock

About InMed Pharmaceuticals Inc

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its pres

https://www.inmedpharma.com

Country: Canada Employees: 13 Industry: Drug Manufacturers - Specialty & Generic

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.269

Positive but modest risk-adjusted returns

Kelly Fraction

-0.0011

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.531

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-49.3%

Historical annualised return based on price data

Max Drawdown

-92.9%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.57

Less volatile than the market — more defensive

52W High

$5.50

71% below the year high

52W Low

$0.58

175% above the year low

Avg Volume

1,686,155

Average daily shares traded — higher means easier to buy and sell

Short Ratio

1.0

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.47

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

6.10

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

34.5%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-162.8%

Profit from core operations before interest and tax

Free Cash Flow

$-3,935,634

Negative — the business is spending more than it generates

Revenue (TTM)

$5M

Total revenue over the last 12 months

Net Income

$-7,836,520

Loss-making — spending exceeds revenue after all costs

Political Trading Activity

Congressional trading disclosures involving this instrument

Date	Politician	Party	Type	Amount
2026-04-21	Ro Khanna	Democrat	Sale	1K–15K
2026-04-20	Ro Khanna	Democrat	Sale	15K–50K

Source: Congressional disclosure filings. View all political trades at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go